Cardiology

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Preeclampsia, gestational diabetes, preterm delivery, large for gestational age, and other hypertensive disorders of pregnancy are now risk factors.

Immediate iFR-guided PCI and deferred cardiac stress MRI-guided PCI showed no significant difference, allowing patients to complete treatment in 1 session.

Patients experienced significantly fewer thromboembolic complications when treated with ICE, indicating its comparatively noninferior safety and efficacy.

The phase 3 ZENITH trial showed sotatercept’s superiority over placebo in reducing morbidity and mortality outcomes in adults with WHO FC III or IV PAH.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

Landers discusses the importance of including multiple specialized professionals and sharing the decision-making process in cardiovascular care.

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Vaidya describes the prognostic approach to pulmonary hypertension in the revised Echocardiographic Assessment of the Right Heart Guidelines.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

Santreva-ATK, the first wire-free endovascular revascularization catheter for crossing chronic total occlusions, is expected to begin sale in October 2025.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Little discusses 2 recently emerged therapies for TR, spotlighting the benefits and limitations associated with each procedure.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.